

Cyrille Touzeau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7312265/publications.pdf>

Version: 2024-02-01

109
papers

4,113
citations

218677

26
h-index

123424

61
g-index

109
all docs

109
docs citations

109
times ranked

4056
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. <i>Blood</i> , 2022, 139, 492-501.	1.4	64
2	Safety and antibody response after one and/or two doses of BNT162b2 Anti- SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. <i>British Journal of Haematology</i> , 2022, 196, 360-362.	2.5	24
3	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	2.5	7
4	Interest of a third dose of BNT162b2 anti- SARS-CoV-2 messenger RNA vaccine after allotransplant. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	21
5	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. <i>Leukemia</i> , 2022, 36, 1066-1077.	7.2	39
6	Molecular Signature of ¹⁸ F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1008-1013.	5.0	4
7	Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy. <i>EJHaem</i> , 2022, 3, 533-536.	1.0	2
8	Anti- SARS-CoV-2 vaccines in recipient and/or donor before allotransplant. <i>EJHaem</i> , 2022, , .	1.0	4
9	B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 279.e1-279.e4.	1.2	10
10	Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. <i>British Journal of Haematology</i> , 2022, 197, 82-96.	2.5	9
11	All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study. <i>Haematologica</i> , 2022, 107, 1693-1697.	3.5	5
12	T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?. <i>Blood</i> , 2022, 139, 3681-3687.	1.4	20
13	Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma. <i>Lancet Haematology</i> , the, 2022, , .	4.6	0
14	Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. <i>British Journal of Haematology</i> , 2022, 198, 988-993.	2.5	5
15	Melflufen for the treatment of multiple myeloma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 371-382.	3.1	3
16	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	2.4	4
17	Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8002-8002.	1.6	8
18	Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8013-8013.	1.6	20

#	ARTICLE	IF	CITATIONS
19	Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. <i>Annals of Hematology</i> , 2021, 100, 285-287.	1.8	1
20	Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 614-627.	2.0	12
21	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta Oncologica</i> , 2021, 60, 466-474.	1.8	4
22	Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. <i>Bone Marrow Transplantation</i> , 2021, 56, 395-399.	2.4	8
23	Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. <i>British Journal of Haematology</i> , 2021, 192, 869-878.	2.5	43
24	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1005-1015.	6.4	35
25	Monoclonal antibodies as an addition to current myeloma therapy strategies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 33-43.	2.4	5
26	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	1.6	98
27	Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 418-427.	4.1	64
28	Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2021, 17, 993-998.	2.4	1
29	Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France: a cohort study using the French National Healthcare database (SNDS). <i>Annals of Hematology</i> , 2021, 100, 1825-1836.	1.8	11
30	No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. <i>British Journal of Haematology</i> , 2021, 194, 635-638.	2.5	7
31	Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies. <i>Journal of Clinical Oncology</i> , 2021, 39, 8048-8048.	1.6	1
32	Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cell recipients. <i>EJHaem</i> , 2021, 2, 520-524.	1.0	28
33	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	1.6	53
34	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1378-1390.	10.7	84
35	Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3911-3911.	1.4	1
36	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. <i>Blood</i> , 2021, 138, 3465-3465.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Comparable Outcomes Among Adult Patients Allografted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study. <i>Blood</i> , 2021, 138, 4914-4914.	1.4	0
38	Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergrroupe Francophone Du My��lome (IFM). <i>Blood</i> , 2021, 138, 83-83.	1.4	4
39	Sensitivity to venetoclax: the B-side of myeloma?. <i>Blood</i> , 2021, 137, 3582-3583.	1.4	0
40	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5406.	4.1	13
41	Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. <i>Scientific Reports</i> , 2020, 10, 15399.	3.3	3
42	RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. <i>EJHaem</i> , 2020, 1, 318-322.	1.0	2
43	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. <i>Cancers</i> , 2020, 12, 2532.	3.7	17
44	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. <i>Annals of Hematology</i> , 2020, 99, 1341-1350.	1.8	7
45	ImmunoPET in Multiple Myeloma��”What? So What? Now What?. <i>Cancers</i> , 2020, 12, 1467.	3.7	8
46	FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. <i>Cancers</i> , 2020, 12, 1384.	3.7	6
47	Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies. <i>Cells</i> , 2020, 9, 717.	4.1	16
48	Imaging of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Cancers</i> , 2020, 12, 486.	3.7	8
49	Newly Diagnosed Myeloma in 2020. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e144-e158.	3.8	9
50	Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2254-2260.	2.4	5
51	Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2020, 136, 10-11.	1.4	6
52	Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts. <i>Blood</i> , 2020, 136, 28-30.	1.4	3
53	Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study. <i>Blood</i> , 2020, 136, 26-26.	1.4	0
54	Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study. <i>Blood</i> , 2020, 136, 15-17.	1.4	0

#	ARTICLE	IF	CITATIONS
55	<p><p>Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patientsâ€™™ selection and perspective</p>. <i>OncoTargets and Therapy</i>, 2019, Volume 12, 5813-5822.</p>	2.0	25
56	<p>The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. <i>BMC Cancer</i>, 2019, 19, 855.</p>	2.6	5
57	<p>Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i>, 2019, 394, 29-38.</p>	13.7	665
58	<p>Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. <i>Annals of Hematology</i>, 2019, 98, 1435-1440.</p>	1.8	30
59	<p>Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. <i>Annals of Hematology</i>, 2019, 98, 1441-1447.</p>	1.8	11
60	<p>Interest of Pet Imaging in Multiple Myeloma. <i>Frontiers in Medicine</i>, 2019, 6, 69.</p>	2.6	34
61	<p>Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. <i>Leukemia and Lymphoma</i>, 2019, 60, 222-225.</p>	1.3	11
62	<p>Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i>, 2019, 134, 1875-1875.</p>	1.4	26
63	<p>The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone. <i>Blood</i>, 2019, 134, 3487-3487.</p>	1.4	3
64	<p>Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells. <i>Blood</i>, 2019, 134, 3109-3109.</p>	1.4	1
65	<p>Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allograft Using Purine Analogue/Busulfan-Based Conditioning Regimen. <i>Blood</i>, 2019, 134, 1985-1985.</p>	1.4	0
66	<p>Ixazomib in the management of relapsed multiple myeloma. <i>Future Oncology</i>, 2018, 14, 2013-2020.</p>	2.4	7
67	<p>Melphalan 140 mg/m² or 200 mg/m² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. <i>Haematologica</i>, 2018, 103, 514-521.</p>	3.5	70
68	<p>Global Approaches in Myeloma: Critical Trials That May Change Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i>, 2018, 38, 656-661.</p>	3.8	4
69	<p>BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. <i>Blood</i>, 2018, 132, 2656-2669.</p>	1.4	57
70	<p>Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ¹⁸F-SUVmax in the FDG-Avid Patients of the IMAJEM Study. <i>Clinical Cancer Research</i>, 2018, 24, 5219-5224.</p>	7.0	24
71	<p>Targeting Bcl-2 for the treatment of multiple myeloma. <i>Leukemia</i>, 2018, 32, 1899-1907.</p>	7.2	109
72	<p>Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. <i>Oncotarget</i>, 2018, 9, 33528-33535.</p>	1.8	17

#	ARTICLE	IF	CITATIONS
73	No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2018, 132, 4577-4577.	1.4	0
74	Fms-like Tyrosine Kinase 3 Ligand Concentration Kinetic Profile during Induction Is Strongly Predictive of Survivals in AML: Results of the FLAM/Flal Study. <i>Blood</i> , 2018, 132, 1484-1484.	1.4	0
75	Influence of Donor Type (sibling vs matched-unrelated donor vs haplo-identical donor vs cord blood) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. <i>Blood</i> , 2018, 132, 3451-3451.	1.4	0
76	The role of SLAMF7 in multiple myeloma: impact on therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 67-75.	3.0	13
77	Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. <i>Expert Review of Hematology</i> , 2017, 10, 207-215.	2.2	18
78	Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). <i>Haematologica</i> , 2017, 102, e112-e114.	3.5	43
79	Daratumumab for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 887-893.	3.1	35
80	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and <sc>JAK</sc> inhibitors era?. <i>European Journal of Haematology</i> , 2017, 99, 60-69.	2.2	5
81	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. <i>Blood</i> , 2017, 130, 2401-2409.	1.4	403
82	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. <i>Blood</i> , 2017, 130, 2392-2400.	1.4	229
83	<sc>BH</sc>3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 179, 684-688.	2.5	26
84	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 445.	4.1	23
85	The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. <i>BMC Cancer</i> , 2016, 16, 802.	2.6	7
86	Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. <i>Blood</i> , 2016, 128, 2808-2818.	1.4	78
87	Predictors of survival in patients with surgical spine multiple myeloma metastases. <i>Surgical Oncology</i> , 2016, 25, 178-183.	1.6	13
88	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861
89	How I treat extramedullary myeloma. <i>Blood</i> , 2016, 127, 971-976.	1.4	134
90	Pomalidomide in the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2016, 12, 1975-1983.	2.4	8

#	ARTICLE	IF	CITATIONS
91	Lymphoid-like Environment, Which Promotes Proliferation and Induces Resistance to BH3-Mimetics, Is Counteracted By Obinutuzumab in MCL: Biological Rationale for the Oasis Clinical Trial. <i>Blood</i> , 2016, 128, 1096-1096.	1.4	1
92	Free Light Chain Escape in Multiple Myeloma : an Exceptional Phenomenon. <i>Blood</i> , 2016, 128, 4428-4428.	1.4	1
93	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. <i>Blood</i> , 2016, 128, 488-488.	1.4	27
94	Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du My��lome (IFM). <i>Blood</i> , 2016, 128, 674-674.	1.4	16
95	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 975-975.	1.4	20
96	Multiple Myeloma: From Front-Line to Relapsed Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e504-e511.	3.8	43
97	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 3100-3104.	1.4	47
98	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. <i>Blood</i> , 2015, 126, 3038-3038.	1.4	16
99	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results. <i>Blood</i> , 2015, 126, 4219-4219.	1.4	11
100	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). <i>Blood</i> , 2015, 126, 727-727.	1.4	32
101	Biological rationale for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. <i>Oncotarget</i> , 2015, 6, 8750-8759.	1.8	70
102	Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation. <i>Blood</i> , 2015, 126, 3218-3218.	1.4	0
103	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. <i>Blood</i> , 2015, 126, 4339-4339.	1.4	0
104	Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Elderly Multiple Myeloma (MM) Patients: A Prospective Multicenter Study. <i>Blood</i> , 2015, 126, 1989-1989.	1.4	0
105	Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier. <i>Blood</i> , 2015, 126, 5519-5519.	1.4	0
106	No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2015, 126, 2520-2520.	1.4	1
107	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014, 93, 233-242.	1.8	17
108	Efficacy of Imatinib-Based Therapy in a Patient with Resistant NUP214-ABL1 T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 4329-4329.	1.4	0

#	ARTICLE	IF	CITATIONS
109	High Grade Non-Hodgkinâ€™s Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis.. Blood, 2006, 108, 2045-2045.	1.4	4